Ruxolitinib

Introduction Overview

Generic Name

ruxolitinib

Brand Name

Jakafi

Dosage Form

oral tablets (5 mg, 10 mg, 15 mg, 20 mg, 25 mg)

Drug Class

Multikinase inhibitors

Pharmacokinetics

Absorption:
Ruxolitinib is rapidly absorbed following oral administration, with peak plasma concentrations typically reached within 1 to 2 hours. The drug exhibits high oral bioavailability, ensuring effective systemic availability for therapeutic action. Food intake does not significantly affect the absorption, allowing it to be administered with or without food, enhancing patient compliance. Studies have shown consistent absorption across various patient populations, including those with hematologic malignancies.

Distribution:
Ruxolitinib demonstrates moderate plasma protein binding, approximately 97%, primarily binding to albumin and alpha-1 acid glycoprotein. It distributes well into various tissues, including blood cells and immune compartments, correlating with its mechanism targeting proliferating hematopoietic cells. The volume of distribution is moderate, suggesting both vascular and extravascular tissue distribution. Tissue penetration into bone marrow and sites of inflammation is clinically significant given the drug's therapeutic targets.

Metabolism:
Ruxolitinib is extensively metabolized in the liver, primarily via cytochrome P450 enzyme CYP3A4, with a minor contribution from CYP2C9. The metabolism involves oxidative pathways yielding hydroxy- and desmethyl metabolites, some of which retain pharmacologic activity though at reduced potency compared to the parent compound. Drug-drug interactions involving CYP3A4 modulators can alter ruxolitinib metabolism, necessitating dose adjustments. Genetic polymorphisms in metabolizing enzymes may influence pharmacokinetics in select populations.

Elimination:
The elimination of ruxolitinib and its metabolites occurs predominantly through renal excretion, with approximately 74% excreted in urine mainly as metabolites and about 22% recovered in feces. The elimination half-life ranges between 3 to 5 hours, supporting twice-daily dosing for sustained therapeutic effect. In patients with renal impairment, clearance is reduced, and dose adjustments are recommended. Hepatic impairment also affects drug clearance due to reduced metabolic capacity. Regular monitoring is suggested to optimize efficacy and minimize toxicity.

Dosage Forms

Available Dosage Forms:
Jakafi is available exclusively as oral tablets in multiple strengths to accommodate dosing individualization: 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg tablets. The tablets contain ruxolitinib phosphate as the active ingredient along with inactive ingredients such as microcrystalline cellulose, lactose monohydrate, magnesium stearate, colloidal silicon dioxide, sodium starch glycolate, povidone, and hydroxypropyl cellulose.

Dosages for Adults and Adolescents:
- For myelofibrosis (MF), dosing is primarily based on baseline platelet counts. Patients with platelet counts >200 x 10^9/L receive 20 mg twice daily; those with platelet counts between 100-200 x 10^9/L receive 15 mg twice daily; and patients with platelet counts between 50 and <100 x 10^9/L start at 5 mg twice daily. Dose adjustments are made based on hematologic parameters and tolerability with regular blood monitoring.
- For polycythemia vera (PV) patients intolerant or refractory to hydroxyurea, a starting dose of 10 mg twice daily is recommended, with subsequent titration depending on response and safety.
- In steroid-refractory acute graft-versus-host disease (aGVHD), the initial recommended dose is 5 mg twice daily, with adjustment according to clinical response.
- For chronic graft-versus-host disease (cGVHD), treatment begins at 10 mg twice daily and may be modified based on therapeutic effect and adverse events.

Specific Patient Populations:
- Pediatric use is approved for GVHD in children aged 12 years and older but has not been established for myelofibrosis or polycythemia vera in children.
- Patients with renal impairment require dose adjustments, especially those on dialysis; Jakafi is recommended after dialysis sessions.
- Hepatic impairment necessitates cautious dosing due to altered metabolism.
- Administration can be via nasogastric tube in patients unable to swallow tablets; healthcare providers should provide specific guidance on this technique.

Clinical guidelines emphasize regular hematologic monitoring during treatment to guide dosing and tolerability. Jakafi is typically administered twice daily, and adherence to the prescribed regimen is critical for optimal outcomes.

Mechanism Of Action

Ruxolitinib, the active component of Jakafi, functions primarily as a selective inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2), both of which are non-receptor tyrosine kinases involved in critical signaling pathways that regulate hematopoiesis and immune function. By competitively binding to the ATP-binding site of these kinases, ruxolitinib prevents phosphorylation and subsequent activation of downstream signal transducers and activators of transcription (STATs). This interruption of the JAK-STAT pathway inhibits aberrant cellular proliferation and cytokine signaling associated with myeloproliferative disorders and inflammatory conditions.

At a cellular level, inhibition of JAK1/JAK2 reduces the hyperactive signaling that drives overproduction of blood cells and inflammatory cytokine release. In myelofibrosis and polycythemia vera, this leads to decreased abnormal clonal proliferation, reduction of splenomegaly, and improvement in disease-related symptoms. In graft-versus-host disease (GVHD), ruxolitinib diminishes the production of inflammatory cytokines, thereby suppressing pathological immune responses responsible for tissue damage.

Biochemically, ruxolitinib's binding stabilizes JAK kinases in an inactive conformation, disrupting downstream signaling cascades essential for the transcription of genes involved in cell growth, differentiation, and immune responses. This molecular specificity underlies its efficacy and contributes to its adverse effect profile by modulating immune cell populations and hematopoiesis.

Clinically, the JAK inhibition mechanism offers therapeutic advantages over traditional cytotoxic agents by targeting signal transduction pathways directly implicated in disease pathogenesis. Comparative studies show that ruxolitinib effectively reduces symptom burden and spleen size in myelofibrosis, and controls hematocrit levels in polycythemia vera, with a more favorable tolerability profile. Ongoing research explores its use in other JAK-STAT mediated diseases and combinational therapies to enhance efficacy and limit resistance.

Pharmacological Actions

Selective inhibition of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) enzymes.
Suppression of aberrant JAK-STAT signaling pathways implicated in myeloproliferative neoplasms.
Reduction of pathological hematopoietic cell proliferation in myelofibrosis and polycythemia vera.
Inhibition of inflammatory cytokine production, modulating immune responses in graft-versus-host disease.
Alleviation of disease-associated symptoms through modulation of immune and hematopoietic pathways.
Promotion of apoptosis in malignant hematopoietic cells via inhibition of growth factor signaling.
Reduction of splenomegaly by targeting abnormal myeloid progenitor expansion.
Modification of the tumor microenvironment by suppressing cytokine-mediated inflammation.
Potential immunosuppressive effects through diminishing T-cell activation and proliferation.
Ability to cross-talk with other kinase pathways due to multikinase inhibitor class characteristics.
Minimal off-target kinase activity leading to a tolerable safety profile compared to pan-kinase inhibitors.
Efficacy in steroid-refractory graft-versus-host disease by reducing immune-mediated tissue damage.
Modulation of lipid metabolism as indicated by observed cholesterol level changes during therapy.
Interaction with hematopoietic stem cell niche influencing marrow fibrosis and disease progression.

Therapeutic Or Clinical Uses

Treatment of intermediate or high-risk myelofibrosis (primary, post-polycythemia vera, and post-essential thrombocytopenia types) in adults.
Management of polycythemia vera in adults intolerant to or inadequately controlled by hydroxyurea.
Treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adults and children aged 12 years and older.
Therapy for chronic graft-versus-host disease (cGVHD) in adults and pediatric patients 12 years and older after failure of one or two systemic therapies.
Reduction of splenomegaly and symptom burden in myelofibrosis patients.
Control of hematocrit and blood cell counts in polycythemia vera to reduce thrombotic events.
Suppression of pathological immune activation in graft-versus-host disease to prevent organ damage.
Potential off-label investigation for other JAK-STAT mediated conditions such as rheumatoid arthritis.
Adjunct for patients refractory to conventional cytoreductive therapies.
Supportive care in hematologic malignancies to improve quality of life and functional status.
Exploration in clinical trials for other malignancies involving JAK pathway dysregulation.
Use in patients with comorbid cardiovascular risk factors under careful monitoring.
Therapeutic option where immunosuppressants are insufficient or contraindicated in GVHD.
Reduction of inflammatory cytokines contributing to systemic symptoms such as fatigue and night sweats.

Side Or Adverse Effects

Thrombocytopenia presenting as low platelet counts, increasing bleeding risk.
Anemia evidenced by reduced red blood cell counts leading to fatigue and dyspnea.
Neutropenia causing increased susceptibility to infections.
Bruising and easy bleeding due to hematologic cytopenias.
Dizziness and headache reported as common neurological side effects.
Diarrhea and gastrointestinal discomfort during treatment.
Swelling or peripheral edema seen in patients with advanced graft-versus-host disease.
Infections including viral, bacterial, and fungal etiologies due to immunosuppression.
Increased risk of non-melanoma skin cancers observed during prolonged therapy.
Elevation of blood cholesterol and triglyceride levels requiring lipid monitoring.
Potential increased risk of major cardiovascular events in patients with preexisting risk factors.
Possible emergence of secondary malignancies such as lymphoma with long-term use.
Serious infections manifesting as fever, chills, rash, and systemic symptoms.
Rare occurrence of thrombosis including deep vein thrombosis and pulmonary embolism.
Injection site irritation or administration-related reactions when given via nasogastric routes.

Precautions

Regular monitoring of complete blood counts to detect early hematologic abnormalities.
Screening for active infections prior to and during treatment, including tuberculosis and hepatitis B.
Cautious use in patients with prior history of malignancy or premalignant conditions.
Avoidance of treatment in pregnancy due to unknown fetal risk; effective contraception is recommended.
Not recommended for breastfeeding mothers; discontinuation advised during therapy and two weeks thereafter.
Dose adjustments or interruptions for cytopenias or significant laboratory abnormalities.
Close monitoring of cardiovascular status in patients with history of smoking or cardiovascular disease.
Patients with hepatic or renal impairment require individualized dose modifications.
Awareness of potential drug interactions influencing metabolism via CYP3A4 and CYP2C9 pathways.
Vaccinations should be updated prior to therapy; live vaccines are generally contraindicated during treatment.
Maintain vigilance for skin changes; periodic dermatologic evaluation is recommended.
Patients should report signs of infection or bleeding immediately to healthcare providers.
Monitoring of lipid panels due to potential drug-induced dyslipidemia.
Consider evaluation for thrombotic events in patients presenting with relevant symptoms.
Adjustment of dosing in children with graft-versus-host disease based on limited pediatric data.

Warnings

Risk of significant cytopenias including thrombocytopenia, anemia, and neutropenia requiring frequent blood tests.
Increased susceptibility to serious and opportunistic infections including tuberculosis and herpes zoster.
Potential development of non-melanoma skin cancers necessitating regular skin examinations.
Elevated cholesterol levels requiring regular biochemical monitoring and possible intervention.
Reported increased risk of major cardiovascular events in populations with existing risk factors and smoking history.
Possibility of life-threatening thromboembolic events like deep vein thrombosis and pulmonary embolism.
Secondary malignancies including lymphoma have been observed with long-term JAK inhibitor use.
Immediate medical attention needed for symptoms of bleeding, infection, or thrombosis during therapy.
Not established as safe or effective in children under 12 years for graft-versus-host disease or in pediatric myelofibrosis or polycythemia vera.
Potential risks during pregnancy and unknown safety in breastfeeding necessitate strict precautions.
Caution advised when co-administered with drugs affecting CYP3A4 to avoid altered ruxolitinib levels.
Patients should avoid abrupt discontinuation to prevent disease flare or rebound of symptoms.
Use with caution in patients with a history of liver or kidney disease to prevent accumulation and toxicity.
Potential for severe allergic reactions or hypersensitivity, although rare, requires awareness.
Risk of worsening pre-existing cardiovascular conditions during therapy.

Contraindication

Known hypersensitivity to ruxolitinib or any of the tablet excipients.
Patients with active serious infections, including untreated tuberculosis or active hepatitis B.
Concurrent use with strong CYP3A4 inducers or inhibitors without appropriate dosage modification.
Pregnancy due to potential teratogenic effects and insufficient safety data.
Breastfeeding mothers should avoid ruxolitinib due to unknown excretion in human milk.
Severe hepatic impairment where metabolism and clearance are profoundly altered.
Severe renal impairment without adequate monitoring and dose adjustment.
History of significant hematologic disorders unrelated to indicated conditions causing excessive cytopenias.
Patients with active malignancies where immunosuppression could complicate treatment.
Use in pediatric patients under 12 years for indications not approved due to lack of established safety.

Drug Interactions

CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) increase plasma concentrations of ruxolitinib, necessitating dose adjustment.
CYP3A4 inducers (e.g., rifampin, carbamazepine) reduce ruxolitinib efficacy by increasing metabolism.
Concomitant use of immunosuppressants may increase infection risk when combined with ruxolitinib.
Drugs causing myelosuppression may have additive hematologic toxicities.
Statins and antihyperlipidemic agents should be monitored closely due to cholesterol changes.
Co-administration with grapefruit or grapefruit juice may elevate plasma drug levels.
Warfarin and other anticoagulants require monitoring for bleeding risk given thrombocytopenia potential.
Vaccines, especially live attenuated, may be less effective and are generally contraindicated during therapy.
Strong CYP2C9 modulators may have minor impacts; clinical significance varies.
Interactions with P-glycoprotein substrates are currently uncertain but warrant monitoring.
Herbal supplements such as St. John's Wort could decrease ruxolitinib efficacy.
Avoid concurrent use of other JAK inhibitors to prevent compounded immunosuppression.
Potential interactions with chemotherapeutic agents requiring careful coordination of care.
Alcohol may exacerbate hepatic strain and should be limited.
Monitoring required when combined with nephrotoxic or hepatotoxic drugs.

Preparations Of The Drug

Jakafi tablets containing ruxolitinib phosphate as the active pharmaceutical ingredient.
Available in strengths of 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg to allow dose titration.
Formulated with inactive ingredients including microcrystalline cellulose, lactose monohydrate, magnesium stearate, colloidal silicon dioxide, sodium starch glycolate, povidone, and hydroxypropyl cellulose for stability and bioavailability.
Oral solid dosage form designed for twice-daily administration.
Tablets are film-coated to improve swallowability and mask taste.
Stable at room temperature between 68°F to 77°F (20°C to 25°C) with standard storage conditions recommended to maintain potency.
Packaging typically includes blister packs or bottles with child-resistant caps.
No generic formulations currently available; Jakafi is marketed exclusively by Incyte Corporation.
Manufactured under rigorous quality controls to assure consistency and safety.
Instructions available for administration via nasogastric tube when oral intake is compromised.
Compliance aids such as pill organizers may be used due to twice-daily dosing schedules.
Dispensed with detailed medication guides highlighting precautions and monitoring requirements.
Produced in accordance with FDA regulations and current good manufacturing practices.
Shelf-life determined by stability testing with periodic re-evaluation to ensure efficacy.
Inactive ingredients chosen to minimize allergenicity and gastrointestinal irritation.